In our study, a total of 15 PCLO mutations were observed in 12 patients, comprising seven AITL patients (21%), four PTCL-NOS patients (40%) and one ALK- ALCL patient (17%) (Fig. 1). This evidence concerns the gene ALK and mature T-cell and NK-cell non-Hodgkin lymphoma.